TRICHLORMETHIAZIDE W/ RESERPINE
Clinical safety rating: safe
MAOIs can cause excitability and hypertension Can cause depression and suicidal ideation.
Trichlormethiazide is a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium and chloride reabsorption, leading to increased diuresis and decreased blood pressure. Reserpine is an adrenergic neuron blocking agent that depletes catecholamines from peripheral sympathetic nerve endings, reducing peripheral vascular resistance and lowering blood pressure.
| Metabolism | Trichlormethiazide is not extensively metabolized; excreted unchanged in urine. Reserpine is extensively metabolized in the liver via hydrolysis and glucuronidation. |
| Excretion | Trichlormethiazide: Renal elimination of unchanged drug (70-80%) and minor biliary/fecal excretion; Reserpine: Renal elimination of metabolites (~60%) and fecal excretion (~40%) with <1% excreted unchanged. |
| Half-life | Trichlormethiazide: 2-3 hours (clinical context: requires multiple daily dosing for sustained diuresis); Reserpine: 50-100 hours (terminal half-life, prolonged due to enterohepatic circulation and tissue binding, leading to sustained antihypertensive effect and risk of accumulation with repeated dosing). |
| Protein binding | Trichlormethiazide: ~78% bound to serum albumin; Reserpine: ~95% bound to plasma proteins (primarily albumin and lipoproteins). |
| Volume of Distribution | Trichlormethiazide: 0.2-0.4 L/kg (confined primarily to extracellular fluid, consistent with low tissue penetration); Reserpine: 9-10 L/kg (extensive tissue binding, particularly to adipose and brain, contributing to prolonged duration). |
| Bioavailability | Trichlormethiazide: Oral bioavailability ~70% (undergoes first-pass metabolism); Reserpine: Oral bioavailability ~50% (extensive first-pass metabolism with hepatic extraction ratio ~0.5). |
| Onset of Action | Oral administration: Trichlormethiazide diuresis begins within 2 hours; Reserpine antihypertensive effect begins within 3-6 days (gradual onset due to slow depletion of catecholamines). |
| Duration of Action | Trichlormethiazide: Diuretic effect lasts 18-24 hours (supports once-daily dosing); Reserpine: Antihypertensive effect persists for 1-2 weeks after discontinuation due to slow recovery of catecholamine stores. |
| Molecular Weight | 516.45 |
Oral: 1 tablet (containing 2 mg trichlormethiazide and 0.1 mg reserpine) once daily, with a maximum of 2 mg trichlormethiazide and 0.2 mg reserpine daily.
| Dosage form | TABLET |
| Renal impairment | CrCl <30 mL/min: contraindicated. CrCl 30-50 mL/min: use with caution and consider dose reduction. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: use with caution; consider dose reduction. Child-Pugh Class C: contraindicated. |
| Pediatric use | Not recommended; safety and efficacy not established. |
| Geriatric use | Start at lowest dose (e.g., 1 tablet daily); monitor for hypotension, electrolyte disturbances, and CNS effects. Avoid use in frail elderly with depression or significant bradycardia. |
| 1st trimester | Avoid due to risk of teratogenicity; reserpine crosses placenta and may cause fetal harm. |
| 2nd trimester | Avoid; diuretics can decrease placental perfusion and cause fetal electrolyte disturbances. |
| 3rd trimester | Avoid; may cause neonatal jaundice, thrombocytopenia, and electrolyte abnormalities. |
Clinical note
MAOIs can cause excitability and hypertension Can cause depression and suicidal ideation.
| FDA category | Animal |
| Placental transfer | Both components cross the placenta; trichlormethiazide is moderately bound and reserpine is highly lipid-soluble, facilitating transfer. |
| Breastfeeding |
■ FDA Black Box Warning
Reserpine has been associated with an increased risk of breast cancer in epidemiological studies; however, causal relationship is unclear. Use caution in patients with history of psychiatric depression, as reserpine may exacerbate or precipitate depression.
| Common Effects | Depression |
| Serious Effects |
Hypersensitivity to thiazides or reserpineAnuriaRenal failureActive peptic ulcer diseaseUlcerative colitisHistory of mental depression (especially with suicidal tendencies)Electroconvulsive therapyPheochromocytomaBreastfeeding
| Precautions | May cause electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), May precipitate gout or hyperuricemia, May increase blood glucose and lipid levels, Reserpine may cause mental depression, peptic ulcer activation, and bradycardia, Caution in patients with impaired renal or hepatic function |
| Food/Dietary |
Loading safety data…
| Both components are excreted in breast milk; reserpine may cause galactorrhea and adverse effects in nursing infants, including nasal congestion and respiratory depression. Use is contraindicated during breastfeeding. |
| Lactation Rating | Avoid |
| Teratogenic Risk | First trimester: Thiazide diuretics are generally not associated with major malformations, but reserpine may increase risk of neonatal respiratory depression and hypothermia. Second and third trimesters: Use may cause fetal or neonatal jaundice, thrombocytopenia, electrolyte imbalance, and hypotension. Reserpine crosses placenta and may cause respiratory depression, bradycardia, and nasal congestion in neonates. Avoid in pregnancy-induced hypertension because of decreased placental perfusion. |
| Fetal Monitoring | Monitor maternal blood pressure, electrolytes, renal function, and fluid balance. Monitor fetal growth and amniotic fluid volume. In neonates, monitor for respiratory depression, bradycardia, jaundice, thrombocytopenia, and electrolyte disturbances. |
| Fertility Effects | Limited data. Reserpine may cause amenorrhea or galactorrhea due to prolactin elevation, potentially affecting fertility. Thiazides may not directly impair fertility but can affect electrolyte balance and overall health. Clinical significance unknown. |
| Avoid high-sodium foods and excessive salt intake, which can reduce antihypertensive effect. Thiazide diuretics may cause potassium depletion; consider increasing intake of potassium-rich foods (e.g., bananas, oranges, potatoes, spinach) unless contraindicated (e.g., renal impairment). Grapefruit juice may interact with reserpine; avoid or limit consumption. Limit alcohol intake as it may potentiate orthostatic hypotension. |
| Clinical Pearls | Combination product: trichlormethiazide (thiazide diuretic) + reserpine (Rauwolfia alkaloid). Monitor for hypotension, especially orthostatic; additive effect with other antihypertensives. Reserpine may cause bradycardia, nasal congestion, and depression (risk increases with dose >0.25 mg/day). Thiazide may cause hypokalemia, hyperglycemia, hyperuricemia. Contraindicated in patients with history of depression, peptic ulcer, or pheochromocytoma. Due to poor safety profile, reserpine is rarely used; consider alternative agents. |
| Patient Advice | Take exactly as prescribed; do not stop abruptly without consulting your doctor. · May cause dizziness or lightheadedness, especially when standing up quickly; avoid driving or operating machinery until you know how this medication affects you. · Avoid alcohol and other medications that lower blood pressure. · Report any symptoms of depression, mood changes, or unusual tiredness to your doctor. · Reserpine can cause nasal congestion; do not use over-the-counter decongestants without advice. · This medication may increase blood sugar; monitor if you have diabetes. · To prevent potassium loss, eat potassium-rich foods (e.g., bananas, oranges) unless directed otherwise by your doctor. · Avoid excessive sun exposure; use sunscreen as this medication may increase sun sensitivity. |